Formidable Fortress ETF
Limited financial coverage for KONG.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Under normal market conditions, the fund seeks to meet its investment objective by investing in large- and mid-cap equity securities, including common stocks and real estate investment trusts (“REITs”). It invests predominantly in common stocks of large- and mid-cap companies (the “Investable Universe”). The fund’s derivative investments may include, among other instruments: (i) options; (ii) volatility-linked ETFs; (iii) volatility-linked exchange-traded notes (“ETNs”).
- CEO
- Augusto Marietti
- IPO
- 2021
- Employees
- 541
- HQ
- Cincinnati, OH, US
Get TickerSpark's AI analysis on KONG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.46M
- Div Yield
- 0.34%
- 52W High
- $33.29
- 52W Low
- $28.66
- 50D MA
- $31.59
- 200D MA
- $30.81
- Beta
- 0.59
- RSI (14)
- 62
- Avg Volume
- 780
No earnings-call transcripts are available for KONG yet.
- Free Float
- 0.0%
- Shares Outstanding
- 680.69K
- Float Shares
- 0
of shares held by institutions
3 13F filers
Held by 1 ETFs
Biggest fund positions in KONG by dollar value.
Our KONG coverage
Recent articles, reports, and earnings notes.
No research on KONG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KONG report →SKILLFUL CRAFTSMAN EDUCATION TECHNOLOGY LIMITED ANNOUNCES ESTABLISHMENT OF HONG KONG SUBSIDIARY TO EXPAND INTERNATIONAL BUSINESS
globenewswire.com · Aug 4
Tokyo Lifestyle Enters Health Product, Cosmetics and Liquors Sale and Purchase Agreement with TASLY HONG KONG to Expand Presence in China
globenewswire.com · Mar 31
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
https://www.prnewswire.com · Apr 25
Entdecken Sie die ultimative Außen-Lebenskunst mit der neue Außenwandleuchte von Govee
https://www.prnewswire.com · May 20
NEW THINKING (HONG KONG) INVESTMENT MANAGEMENT CO..
gurufocus.com · Feb 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.